Emily Field
Stock Analyst at Barclays
(1.52)
# 3,405
Out of 5,149 analysts
15
Total ratings
62.5%
Success rate
-0.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underweight | $25 | $26.58 | -5.94% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $119.83 | +16.83% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $147.83 | +4.85% | 1 | Feb 20, 2026 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $1,350 | $1,007.73 | +33.96% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $61.22 | +22.51% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $184.02 | +0.53% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $377.00 | -7.16% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $233.86 | +17.59% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $36.66 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $33.05 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $57.07 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $748.72 | - | 1 | Oct 19, 2021 |
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $26.58
Upside: -5.94%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $119.83
Upside: +16.83%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $147.83
Upside: +4.85%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $1,007.73
Upside: +33.96%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $61.22
Upside: +22.51%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $184.02
Upside: +0.53%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $377.00
Upside: -7.16%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $233.86
Upside: +17.59%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $36.66
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $33.05
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $57.07
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $748.72
Upside: -